Effects of early postnatal allopregnanolone administration on elevated plus maze anxiety scores in adult male wistar rats

Neuropsychobiology

Volumn 65, Issue 1, 2011, Pages 20-27

  Darbra, Sònia ^a   Pallarès, Marc ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Allopreganolone; Anxiety; Development; Elevated plus maze; GABAA modulators; Midazolam; Neurosteroids

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; BENZODIAZEPINE; MIDAZOLAM;

ADULTHOOD; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; BRAIN DEVELOPMENT; ENVIRONMENTAL STRESS; FEMALE; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MIDAZOLAM; NEUROTRANSMITTER AGENTS; PREGNANOLONE; RATS; RATS, WISTAR; RECEPTORS, GABA-A;

EID: 81155148724     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000328161     Document Type: Article

References (42)

1. Mellon SH, Griffin LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 2002; 13: 35-43. (Pubitemid 36734014)
2. Frye CA, Rhodes ME, Petraglia SM, Walf AA, Sumida K, Edinger KL: 3α-hydroxy-5α- pregnan-20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors. Neuroscience 2006; 138: 1007-1014.
3. Follesa P, Biggio F, Caria S, Gorini G, Biggio G: Modulation of GABA(A) receptor gene expression by allopregnanolone and ethanol. Eur J Pharmacol 2004; 500: 413-425. (Pubitemid 39304024)
4. Mameli M, Carta M, Partridge LD, Valenzuela CF: Neurosteroid-induced plasticity of immature synapses via retrograde modulation of presynaptic NMDA receptors. J Neurosci 2005; 25: 2285-2294. (Pubitemid 40322269)
5. Grobin AC, Heenan EJ, Lieberman JA, Morrow AL: Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex. J Neurosci 2003; 23: 1832-1839. (Pubitemid 36314738)
6. Gizerian SS, Morrow AL, Lieberman JA, Grobin AC: Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats. Brain Res 2004; 1012: 66-74. (Pubitemid 38648900)
7. Muneoka KT, Borella A, Whitaker-Azmitia PM: Transient expression of S-100beta immunostaining in developing thalamus and somatosensory cortex of rat. Brain Res Dev Brain Res 2003; 142: 101-104. (Pubitemid 36593153)
8. Muneoka KT, Takigawa M: A neuroactive steroid, pregnenolone, alters the striatal dopaminergic tone before and after puberty. Neuroendocrinology 2002; 75: 288-295. (Pubitemid 34518766)
9. Mtchedlishvili Z, Sun CS, Harrison MB, Kapur J: Increased neurosteroid sensitivity of hippocampal GABAA receptors during postnatal development. Neuroscience 2003; 118: 655-666. (Pubitemid 36506954)
10. Shirayama Y, Muneoka KT, Iwata M, Ishida H, Hazama G, Kawahara R: Pregnenolone and dehydroepiandrosterone administration in neonatal rats alters the immunoreactivity of hippocampal synapsin I, neuropeptide Y and glial fibrillary acidic protein at post-puberty. Neuroscience 2005; 133: 147-157. (Pubitemid 40694165)
11. Bitran D, Dugan M, Renda P, Ellis R, Foley M: Anxiolytic effects of the neuroactive steroid pregnanolone (3alpha-OH-5 beta-pregnan- 20-one) after microinjection in the dorsal hippocampus and lateral septum. Brain Res 1999; 850: 217-224.
12. Martin-Garcia E, Pallares M: Intrahippocampal nicotine and neurosteroids effects on the anxiety-like behaviour in voluntary and chronic alcohol-drinking rats. Behav Brain Res 2005a;164: 117-127. (Pubitemid 41253740)
13. Martin-Garcia E, Pallares M: The intrahippocampal administration of the neurosteroid allopregnanolone blocks the audiogenic seizures induced by nicotine. Brain Res 2005b;1062: 144-150. (Pubitemid 41612137)
14. Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG, Harris GS: Inhibition of ratα-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997; 61: 55-64. (Pubitemid 27395742)
15. Mukai Y, Higashi T, Nagura Y, Shimada K: Studies on neurosteroids XXV: influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol Pharm Bull 2008; 31: 1646-1650.
16. Martin-Garcia E, Darbra S, Pallares M: Neonatal finasteride induces anxiogenic-like profile and deteriorates passive avoidance in adulthood after intrahippocampal neurosteroid administration. Neuroscience 2008; 154: 1497-1505.
17. Darbra S, Pallares M: Neonatal allopregnanolone increases novelty-directed locomotion and disrupts behavioural responses to GABAA receptors modulators in adulthood. Int J Dev Neurosci 2009; 27: 617-625.
18. Darbra S, Pallares M: Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood. Psychoneuroendocrinology 2010; 35: 525-535.
19. Handley SL, McBlane JW: An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 1993; 29: 129-138. (Pubitemid 23193181)
20. Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167. (Pubitemid 16239568)
21. Manhaes AC, Guthierrez MC, Filgueiras CC, Abreu-Villaça Y: Anxiety-like behavior during nicotine withdrawal predict subsequent nicotine consumption in adolescent C57BL/6 mice. Behav Brain Res 2008; 193: 216-224.
22. Rodgers RJ, Johnson NJ: Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 1995; 52: 297-303.
23. Gizerian SS, Moy SS, Lieberman JA, Grobin AC: Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity. Psychopharmacology (Berl) 2006; 86: 334-342. (Pubitemid 43800835)
24. Grobin AC, Gizerian S, Lieberman JA, Morrow AL: Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats. Neuroscience 2006; 138: 809-819.
25. Mitev YA, Darwish M, Wolf SS, Holsboer F, Almeida OF, Patchev VK: Gender differences in the regulation of 3 alpha-hydroxysteroid dehydrogenase in rat brain and sensitivity to neurosteroid-mediated stress protection. Neuroscience 2003; 120: 541-549. (Pubitemid 37288788)
26. Zimmerberg B, Kajunski EW: Sexually dimorphic effects of postnatal allopregnanolone on the development of anxiety behavior after early deprivation. Pharmacol Biochem Behav 2004; 78: 465-471. (Pubitemid 38901014)
27. Dawson GR, Tricklebank MD: Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 1995; 16: 33-36.
28. Bertoglio LJ, Carobrez AP: Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav Brain Res 2002; 132: 135-143. (Pubitemid 34462041)
29. García AM, Cárdenas FP, Morato S: Effect of different illumination levels on rat behavior in the elevated plus-maze. Physiol Behav 2005; 85: 265-270. (Pubitemid 40840742)
30. Jones N, King SM: Influence of circadian phase and test illumination on preclinical models of anxiety. Physiol Behav 2001; 72: 99-106. (Pubitemid 32184798)
31. Violle N, Balandras F, Le Roux Y, Desor D, Schroeder H: Variations in illumination, closed wall transparency and/or extramaze space influence both baseline anxiety and response to diazepam in the rat elevated plusmaze. Behav Brain Res 2009; 203: 35-42.
32. Arendt RM, Greenblatt DJ, deJong RH, Bonin JD, Abernethy DR, Ehrenberg BL, Giles HG, Sellers EM, Shader RI: In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 1983; 227: 98-106. (Pubitemid 14205275)
33. Cruz AP, Frei F, Graeff FG: Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994; 49: 171-176. (Pubitemid 24297273)
34. Treit D, Menard J, Royan C: Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 1993; 44: 463-469.
35. Rodgers RJ, Dalvi A: Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 1997; 21: 801-810.
36. Albrechet-Souza L, Oliveira AR, De Luca MC, Tomazini FM, Santos NR, Brandao ML: A comparative study with two types of elevated plus-maze (transparent vs. opaque walls) on the anxiolytic effects of midazolam, one-trial tolerance and fear-induced analgesia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 571-579. (Pubitemid 40603833)
37. Rosa VP, Vandresen N, Calixto AV, Kovaleski DF, Faria MS: Temporal análisis of the rat's behavior in the plus-maze: effects of midazolam. Pharmacol Biochem Behav 2000; 67: 177-182.
38. Savić MM, Obradović DI, Ugresić ND, Cook JM, Sarma PV, Bokonjić DR: Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt. Psychopharmacology (Berl) 2005; 180: 455-465. (Pubitemid 40905035)
39. Wang JM, Brinton RD: Allopregnanoloneinduced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci 2008;(suppl 2):S11.
40. + progenitor proliferation. J Neurosci Res 2004; 78: 770-783. (Pubitemid 39657565)
41. Mellon SH: Neurosteroid regulation of central nervous system development. Pharmacol Ther 2007; 116: 107-124. (Pubitemid 47391034)
42. Hall JR, Benning SD, Patrick CJ: Criterionrelated validity of the three-factor model of psychopathy: personality, behavior, and adaptive functioning. Assessment 2004; 11: 4-16. (Pubitemid 44534398)